De Novo
DEN200026: EndeavorRx
FDA De Novo · akili interactive labs inc. · decided Jun 15, 2020
Key facts
| De Novo number | DEN200026 |
|---|---|
| Device name | EndeavorRx |
| Applicant | akili interactive labs inc. |
| Product code | QFT |
| Date received | Apr 16, 2020 |
| Decision date | Jun 15, 2020 |
| Decision | granted (DENG) |
| FDA classification | Class II |
| Review panel | Neurology |
| FEI number | 3013341423 |
At a glance
- 1–9 Later 510(k)s citing this De Novo
- 1–9 UDI device identifiers (GUDID)
- None MAUDE adverse event reports
- None Recall events
- No Decision summary on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About De Novo classification requests
The De Novo pathway classifies novel low- to moderate-risk devices that have no legally marketed predicate; each granted request creates a new classification regulation and product code.
Source: U.S. Food and Drug Administration (FDA), De Novo database · Source date: